Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy

Table 2 Variables associated with improved therapeutic outcomes of anti-tumor necrosis factor maintenance therapy in patients with perianal fistulizing Crohn’s disease

Variables	Ref.
Clinical or phenotypic
Ileocolonic disease	[6]
Concomitant immunosuppressants	[6]
Duration of seton drainage (< 34 wk)	[6]
Duration of infliximab treatment (> 118 wk)	[6]
Number of infliximab infusions (> 19)	[6]
Absence of complex fistulas	[14]
Male gender	[26]
Absence of switch of anti-TNF therapy	[11]
Imaging
Absence of persisting fistulas on MRI	[5]
Absence of collections at baseline on MRI	[5]
Absence of rectal wall involvement on MRI	[5]
Absence of single-branched fistulas on MRI	[5]
Absence of rectal involvement on MRI	[11]
Serologic
Infliximab (maintenance) trough concentrations ≥ 10.1 μg/mL	[26]
Endoscopic
Absence of active proctitis	[11]

TNF: Tumor necrosis factor; MRI: Magnetic resonance imaging.